

Not for Retail distribution: this document is intended exclusively for Professional, Institutional, Qualified or Wholesale Investors / Clients, as defined by applicable local laws and regulation. Circulation must be restricted accordingly.

Asian Credit Strategies As 2021 begins, market risks favour HY

- Potential for rising rates, low overall yields, and a large spread differential with HY limits IG appeal
- Wide dispersion of spread within HY underscores a high level of idiosyncratic risk
- Careful credit selection along with a significant spread cushion justifies HY positioning over IG

Jim Veneau and Christy Lee Portfolio Managers, Asian Credit

What's happening?

The J.P. Morgan Asia Credit Index (JACI) ended the tumultuous year in positive territory, delivering +0.64% of total return in December. A total of 10 bonds from 7 issuers defaulted within the JACI that closed the year with a default rate at 1.24%. As of 31st December, the index was represented by 612 issuers, with a market capitalization amounting to US\$ 1.20 trillion. December's good performance was driven by tighter spreads, which outweighed weaker interest rates. Credit wise, HY names (+1.96%) significantly outperformed their IG counterparts (+0.20%), benefitting from more spread compression, as well as more cushion against rising interest rates, owing to shorter structural duration. The Sovereign segment bottomed the performance chart, dragged by the worst mover Sri Lanka (-3.56% on December). The year-end also saw the JACI's Yield to Worst falling below the psychological barrier of 3% - a record-low - driven by the drop in Interest Rates, while Biden's strong fiscal stimulus plan suggests higher rates for 2021. The JACI's spread level ended the year around 28 bps above its January level, most sectors have fully recovered with spreads trading near their pre-Covid marks, particularly on the IG space. Heading into 2021, there seems to be more room for spread compression on HY, credit differentiation will be key amid a fragile outlook.

Asian Credit Market* Valuation



Monthly Returns:

J.P. Morgan Asia Credit Index (JACI) +0.64%



Investment Grade +0.25%			High Yield +1.96%		
Corporates	Sovereign	Quasi-Sov	Corporates	Sovereign	Quasi-Sov
+0,39%	-0,08%	+0,14%	+2.30%	-0.98%	+0.46%

Portfolio positioning and performance:

	Performance	
Country /Sector:	OW exposure on China Property and Indonesia was beneficial, as well as UW on Frontier Sovereign. Our neutral Indian positioning was helped by a positive selection effect, driven by VEDLN's rally.	+
DTS:	Maintained neutral DTS for AHY and reduced DTS for ASD. The short duration biased was helpful amid rising interest rates	+
Bottom-up:	Selection effect was slightly negative on balance, mainly dragged lower by our UW on EVERRE that saw some retracement in December, costing 16 bps of relative performance. OW positioning on VEDLN and THSCPA was beneficial.	-

Outlook

The year has begun with quick reminders to both investment grade and high yield investors what risks need attention in 2021. A quick surge in UST yields on the heels of victories for Democrats in Georgia's runoff U.S. Senate races has created losses for investment grade bonds, particularly those of longer duration. Much less sensitive to rising UST yields, Asian high yield bonds are off to a positive but choppy start. Higher yields mean higher risks both in the form of fundamental challenges and sentiment driven volatility, both of which have been on display early in 2021. Low nominal yields and a potentially rising interest rate environment have clearly diminished the appeal of investment grade bonds and pushed more investors into high yield exposures where there is a 400 to 500 basis point spread pickup. This provides a lot of cushion for periods when bond prices fall and, conversely, offers the opportunity for total return enhancement credit trends improve and an issuer's bond spreads compress. High yield China property developers and Indonesia corporates maintain attractive yield levels but idiosyncratic risks as a result of high leverage, poor governance, liquidity challenges and operational challenges exacerbated by the pandemic require careful consideration. In such an environment, investor sentiment as well as supply and demand technical factors should not be overlooked for investors with limited loss tolerance. With careful credit selection, we remain in favour of high yield exposure over investment grade with portfolios positioned for shorter duration. With a weak to stable USD unhedged, higher yielding local currency can be considered.



No assurance can be given that the Asian Credit Strategy will be successful. Investors can lose some or all of their capital invested. The Asian Credit Strategy is subject to risks including Credit risk, Liquidity risk, Derivatives and leverage, Investments in specific countries or geographical zones, Sovereign debt, Emerging markets, High yield debt securities, Contingent convertible bonds.

Not for Retail distribution: This document is intended exclusively for Professional, Institutional, Qualified or Wholesale Clients / Investors only, as defined by applicable local laws and regulation. Circulation must be restricted accordingly.

Past performance is not a guide to current or future performance, and any performance or return data displayed does not take into account commissions and costs.

This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities.

Due to its simplification, this document is partial and opinions, estimates and forecasts herein are subjective and subject to change without notice. There is no guarantee forecasts made will come to pass. Data, figures, declarations, analysis, predictions and other information in this document is provided based on our state of knowledge at the time of creation of this document. Whilst every care is taken, no representation or warranty (including liability towards third parties), express or implied, is made as to the accuracy, reliability or completeness of the information contained herein. Reliance upon information in this material is at the sole discretion of the recipient. This material does not contain sufficient information to support an investment decision.

Issued by AXA INVESTMENT MANAGERS PARIS, a company incorporated under the laws of France, having its registered office located at Tour Majunga, 6 place de la Pyramide, 92800 Puteaux, registered with the Nanterre Trade and Companies Register under number 353 534 506, and a Portfolio Management Company, holder of AMF approval no. GP 92-08, issued on 7 April 1992. In other jurisdictions, this document is issued by AXA Investment Managers SA's affiliates in those countries.

In Hong Kong, this document is issued by AXA Investment Managers Asia Limited (SFC License No. AAP809), which is authorized and regulated by Securities and Futures Commission. This document is to be used only by persons defined as "professional investor" under Part 1 of Schedule 1 to the Securities and Futures Ordinance (SFO) and other regulations, rules, guidelines or circulars which reference "professional investor" as defined under Part 1 of Schedule 1 to the SFO. This document must not be relied upon by retail investors. Circulation must be restricted accordingly.

In Singapore, this document is issued by AXA Investment Managers Asia (Singapore) Ltd. (Registration No. 199001714W) and is intended for the use of Institutional Investors only as defined in Section 4A of the Securities and Futures Act (Cap. 289) and must not be relied upon by retail investors. Circulation must be restricted accordingly.

In Taiwan, this document is issued by AXA Investment Managers Asia Limited (SFC License No. AAP809), which is authorized and regulated by Securities and Futures Commission. This document and the information contained herein are intended for the use of professional or institutional investors and should not be relied upon by retail investors. They have been prepared and issued for private informational and educational purposes only at the sole request of the specified recipients, and not intended for general circulation. They are strictly confidential, and must not be reproduced, circulated, distributed, redistributed or otherwise used, in whole or in part, in any way without the prior written consent of AXA IM Asia. They are not intended for distribution to any persons or in any jurisdictions for which it is prohibited.

If any fund is highlighted in this communication (the "Fund"), its offering document or prospectus contains important information on selling restrictions and risk factors, you should read them carefully before entering into any transaction. It is your responsibility to be aware of and to observe all applicable laws and regulations of any relevant jurisdiction. AXA IM Asia does not intend to offer any Fund in any country where such offering is prohibited.

The offer, distribution, sale or re-sale of fund units/shares in Taiwan requires approval from and/or registration with Taiwanese regulatory authorities. To the extent that any units/shares of the Funds are not so licensed or registered, such units/shares are made available in Taiwan on a private placement basis only to banks, bills houses, trust enterprises, financial holding companies and other qualified entities or institutions (collectively, "Qualified Institutions") and other entities and individuals meeting specific criteria ("Other Qualified Investors") pursuant to the private placement provisions of the Rules Governing Offshore Funds. No other offer or sale of such units/shares in Taiwan is permitted. Taiwanese purchasers of such units/shares may not sell or otherwise dispose of their holdings except by redemption, transfer to a Qualified Institution or Other Qualified Investor, transfer by operation of law or other means approved by the Taiwan Financial Supervisory Commission.

For Malaysian investors: As the recognition by the Malaysian Securities Commission pursuant to Section 212 of the Malaysian Capital Markets and Services Act 2007 has not been / will not be obtained nor will this document be lodged or registered with the Malaysian Securities Commission, the shares referred to hereunder (if any) are not being and will not be deemed to be issued, made available, offered for subscription or purchase in Malaysia and neither this document nor any other document or other material in connection therewith should be distributed, caused to be distributed or circulated in Malaysia.

For Thailand investors: Nothing in this document shall constitute in any manner whatsoever a proposal to make available, offer for subscription or purchase or to issue an invitation to purchase or subscribe for any securities in Thailand or a proposal to implement any of the foregoing in Thailand nor has this document been approved by or registered with the Securities and Exchange Commission of Thailand ("SEC"). No person receiving a copy of this document may treat the

AXA IM - RESTRICTED



same as constituting an invitation or offer to him in Thailand and such person shall not distribute or make available this document in Thailand. The issuer of this document shall not be liable in any manner whatsoever in the event this document is distributed or made available to any person in Thailand receiving a copy of this document. Since no application for approval has been or will be made to the SEC for the offering of the securities, or for the registration of this document, the securities shall not be offered for subscription or purchased or made available, whether directly or indirectly, in Thailand. It is the sole responsibility of recipients wishing to take any action upon this document to satisfy themselves as to the full observance of the laws of Thailand, to comply with all relevant government and regulatory approvals, and to comply with all applicable laws, including but not limited to exchange control laws.